MX358176B - El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea. - Google Patents

El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.

Info

Publication number
MX358176B
MX358176B MX2013013707A MX2013013707A MX358176B MX 358176 B MX358176 B MX 358176B MX 2013013707 A MX2013013707 A MX 2013013707A MX 2013013707 A MX2013013707 A MX 2013013707A MX 358176 B MX358176 B MX 358176B
Authority
MX
Mexico
Prior art keywords
corneal
keratoconus
riboflavin
treatment
well
Prior art date
Application number
MX2013013707A
Other languages
English (en)
Inventor
Stagni Marcello
Stagni Edoardo
Filippello Massimo
Cavallo Giovanni
Sodo Eugenio
Original Assignee
Sooft Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX358176(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sooft Italia Spa filed Critical Sooft Italia Spa
Publication of MX358176B publication Critical patent/MX358176B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe aquí el uso de intensificadores posiblemente con riboflavina, así como las composiciones correspondientes para el tratamiento de queratocono u otras alteraciones ectásicas de la córnea, por medio del método de reticulación de la córnea.
MX2013013707A 2008-08-28 2009-08-27 El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea. MX358176B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2008A000472A IT1393402B1 (it) 2008-08-28 2008-08-28 Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali
PCT/IT2009/000392 WO2010023705A1 (en) 2008-08-28 2009-08-27 Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders

Publications (1)

Publication Number Publication Date
MX358176B true MX358176B (es) 2018-08-08

Family

ID=40679354

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013013707A MX358176B (es) 2008-08-28 2009-08-27 El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.
MX2011002234A MX2011002234A (es) 2008-08-28 2009-08-27 El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para la reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la cornea.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011002234A MX2011002234A (es) 2008-08-28 2009-08-27 El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para la reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la cornea.

Country Status (18)

Country Link
US (1) US20110152219A1 (es)
EP (1) EP2323642B1 (es)
JP (1) JP2012500844A (es)
KR (1) KR20110046567A (es)
CN (1) CN102164592B (es)
AU (1) AU2009286285B2 (es)
BR (1) BRPI0910368B8 (es)
CL (1) CL2011000378A1 (es)
DK (1) DK2323642T3 (es)
EA (2) EA022055B1 (es)
ES (1) ES2460578T3 (es)
IL (1) IL211448A (es)
IT (1) IT1393402B1 (es)
MX (2) MX358176B (es)
PE (1) PE20110287A1 (es)
PL (1) PL2323642T3 (es)
PT (1) PT2323642E (es)
WO (1) WO2010023705A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545487B2 (en) 2007-12-05 2013-10-01 Avedro Inc. Eye therapy system
US8366689B2 (en) 2008-09-30 2013-02-05 Avedro, Inc. Method for making structural changes in corneal fibrils
US8574277B2 (en) 2009-10-21 2013-11-05 Avedro Inc. Eye therapy
US9707126B2 (en) 2009-10-21 2017-07-18 Avedro, Inc. Systems and methods for corneal cross-linking with pulsed light
WO2011116306A2 (en) 2010-03-19 2011-09-22 Avedro, Inc. Systems and methods for applying and monitoring eye therapy
US20110280763A1 (en) * 2010-05-17 2011-11-17 Abbott Medical Optics Inc. Light-activated disinfection system
IT1400982B1 (it) 2010-07-05 2013-07-05 Pinelli Collirio osmotico trans-epiteliale per la cura del cheratocono.
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
MX2013008042A (es) * 2011-01-12 2013-09-16 Sooft Italia Spa Suministro a la cornea de agentes de reticulacion mediante iontoforesis, para el tratamiento del queratocono y composiciones oftalmicas relacionadas.
PT2648663E (pt) 2011-01-12 2015-07-29 Sooft Italia S P A Dispositivo para administração por iontoforese de riboflavina na córnea para o tratamento de queratocone
WO2012158991A2 (en) * 2011-05-18 2012-11-22 Avedro, Inc. Controlled application of cross-linking agent
US9044308B2 (en) 2011-05-24 2015-06-02 Avedro, Inc. Systems and methods for reshaping an eye feature
US9020580B2 (en) 2011-06-02 2015-04-28 Avedro, Inc. Systems and methods for monitoring time based photo active agent delivery or photo active marker presence
ITRM20110560A1 (it) * 2011-10-25 2013-04-26 Sooft Italia Spa Migliorata composizione di cross-linking per il trattamento del cheratocono mediante iontoforesi
RU2481809C1 (ru) * 2011-12-21 2013-05-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения кератэктазии после лазик
EP2830627B1 (en) * 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP2830554A1 (en) 2012-03-29 2015-02-04 CXL Ophthalmics, LLC Ocular cross-linking system and method for sealing corneal wounds
RU2487691C1 (ru) * 2012-04-12 2013-07-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения кератоконуса
PT2948113T (pt) * 2013-01-28 2018-05-22 Novartis Ag Aparelho para formação corneal de ligações cruzadas
EP2999471B1 (en) * 2013-05-19 2020-12-16 Avedro, Inc. Systems, methods, and compositions for cross-linking
US9498114B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
US9498122B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
RU2542799C1 (ru) * 2013-10-29 2015-02-27 Игорь Борисович Медведев Способ лечения кератоконуса роговицы
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
US11666777B2 (en) 2014-05-12 2023-06-06 Gholam A. Peyman Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient
US10709546B2 (en) 2014-05-12 2020-07-14 Gholam A. Peyman Intracorneal lens implantation with a cross-linked cornea
US11338059B2 (en) 2014-05-12 2022-05-24 Gholam A. Peyman Method of corneal and scleral inlay crosslinking and preservation
US10278920B1 (en) 2014-05-12 2019-05-07 Gholam A. Peyman Drug delivery implant and a method using the same
US11259914B2 (en) 2014-05-12 2022-03-01 Gholam A. Peyman Molding or 3-D printing of a synthetic refractive corneal lenslet
US11045352B2 (en) 2014-05-12 2021-06-29 Gholam A. Peyman Methods for treatment of dry eye and other acute or chronic inflammatory processes
US10314690B1 (en) 2014-05-12 2019-06-11 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US10881503B2 (en) 2014-05-12 2021-01-05 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US10925889B2 (en) 2014-05-12 2021-02-23 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US10583221B2 (en) 2014-05-12 2020-03-10 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US9744029B1 (en) 2014-05-12 2017-08-29 Gholam A. Peyman Method of preventing capsular opacification and fibrosis utilizing an accommodative intraocular lens implant
US11648261B2 (en) 2014-05-12 2023-05-16 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11565023B2 (en) 2014-05-12 2023-01-31 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US9427355B1 (en) * 2014-05-12 2016-08-30 Gholam A. Peyman Corneal transplantation with a cross-linked cornea
US12396889B2 (en) 2014-05-12 2025-08-26 Gholam A. Peyman Lamellar corneal autologous or homologous graft in refractive surgery
US9937033B1 (en) 2014-05-12 2018-04-10 Gholam A. Peyman Corneal lenslet implantation with a cross-linked cornea
US12383393B2 (en) 2014-05-12 2025-08-12 Gholam A. Peyman Ablatable corneal inlay for correction of refractive errors and/or presbyopia
US10195081B1 (en) 2014-05-12 2019-02-05 Gholam A. Peyman Method of prevention of capsular opacification and fibrosis after cataract extraction and/or prevention of fibrosis around a shunt or stent after glaucoma surgery
US10206569B1 (en) 2014-05-12 2019-02-19 Gholam A. Peyman Corneal intraocular pressure sensor and a surgical method using the same
JP6644799B2 (ja) 2014-10-27 2020-02-12 アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． 眼の架橋処置のためのシステム及び方法
US10114205B2 (en) 2014-11-13 2018-10-30 Avedro, Inc. Multipass virtually imaged phased array etalon
US10258809B2 (en) 2015-04-24 2019-04-16 Avedro, Inc. Systems and methods for photoactivating a photosensitizer applied to an eye
SI3288588T1 (sl) 2015-04-29 2018-12-31 Sooft Italia S.P.A. Izboljšana sredstva za prečno povezovanje kolagenskih vlaken za uporabo pri zdravljenju kornealne ektazije
EP4483884A3 (en) 2015-05-22 2025-03-05 Avedro Inc. Systems for monitoring cross-linking activity for corneal treatments
KR102706856B1 (ko) 2015-07-21 2024-09-19 아베드로 인코퍼레이티드 광증감제로 눈을 치료하기 위한 시스템 및 방법
CN105256059B (zh) * 2015-11-20 2019-01-18 山东省眼科研究所 Tuba3d基因在制备圆锥角膜诊断制品中的应用
ITUB20160237A1 (it) 2016-01-26 2017-07-26 Vision Engineering Italy Soc A Responsabilita Limitata Apparato di controllo del dosaggio di un agente cromoforo in un tessuto corneale e procedimento per dosare un agente cromoforo in un tessuto corneale
EP3442481B1 (en) 2016-04-13 2023-06-28 Avedro, Inc. Systems for delivering drugs to an eye
WO2018156593A1 (en) * 2017-02-21 2018-08-30 Avedro, Inc. Formulations for eye treatments
WO2019173403A1 (en) 2018-03-05 2019-09-12 Avedro, Inc. System for eye tracking during eye treatment
EP3761928A1 (en) 2018-03-08 2021-01-13 Avedro, Inc. Micro-devices for treatment of an eye
CA3112932A1 (en) 2018-09-19 2020-03-26 Avedro, Inc. Systems and methods for eye tracking during eye treatment
JP7504083B2 (ja) 2018-09-19 2024-06-21 アヴェドロ・インコーポレーテッド 角膜拡張障害を治療するシステム及び方法
WO2020077015A1 (en) 2018-10-09 2020-04-16 Avedro, Inc. Photoactivation systems and methods for corneal cross-linking treatments
US12171691B2 (en) 2019-02-26 2024-12-24 Avedro, Inc. Systems and methods for cross-linking treatments of an eye
US12226478B2 (en) 2019-04-28 2025-02-18 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11707518B2 (en) 2019-04-28 2023-07-25 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
WO2021026405A1 (en) 2019-08-06 2021-02-11 Avedro, Inc. Photoactivation systems and methods for corneal cross-linking treatments
CN110314034B (zh) * 2019-08-08 2021-12-03 南京市第一医院 一种可实现个性治疗的角膜交联装置
US11458220B2 (en) 2020-11-12 2022-10-04 Singletto Inc. Microbial disinfection for personal protection equipment
WO2022192237A1 (en) 2021-03-08 2022-09-15 Avedro, Inc. Systems and methods for generating patient-specific corneal cross-linking treatment patterns
CN115177729B (zh) * 2022-08-03 2023-09-26 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 肾上腺素受体激动剂在制备圆锥角膜交联促渗剂中的应用
US12359369B2 (en) 2022-08-11 2025-07-15 Singletto Inc. Skin protection against microbial particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
JP2002506013A (ja) 1998-03-09 2002-02-26 イスタ ファーマシューティカルズ インコーポレイテッド 酵素角膜矯正術における角膜硬化剤の使用
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
JP5101778B2 (ja) * 2000-02-11 2012-12-19 ザ ジェネラル ホスピタル コーポレイション 光化学作用による組織接着
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
ITRM20050443A1 (it) * 2005-08-12 2007-02-13 Opocrin Spa Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea.
WO2011019940A2 (en) * 2009-08-12 2011-02-17 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method for use

Also Published As

Publication number Publication date
BRPI0910368B1 (pt) 2020-01-28
EP2323642A1 (en) 2011-05-25
EA023607B1 (ru) 2016-06-30
WO2010023705A1 (en) 2010-03-04
ITRM20080472A1 (it) 2010-02-28
AU2009286285B2 (en) 2015-03-26
IT1393402B1 (it) 2012-04-20
BRPI0910368B8 (pt) 2021-05-25
PE20110287A1 (es) 2011-05-15
EA022055B1 (ru) 2015-10-30
EA201100393A1 (ru) 2011-10-31
CN102164592A (zh) 2011-08-24
CN102164592B (zh) 2015-09-23
IL211448A0 (en) 2011-05-31
MX2011002234A (es) 2011-04-05
AU2009286285A1 (en) 2010-03-04
JP2012500844A (ja) 2012-01-12
EA201300272A1 (ru) 2013-07-30
PL2323642T3 (pl) 2014-07-31
EP2323642B1 (en) 2014-02-19
KR20110046567A (ko) 2011-05-04
IL211448A (en) 2016-05-31
PT2323642E (pt) 2014-05-15
DK2323642T3 (da) 2014-05-05
ES2460578T3 (es) 2014-05-13
BRPI0910368A2 (pt) 2015-10-13
CL2011000378A1 (es) 2011-06-10
US20110152219A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
BRPI0910368B8 (pt) uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
CR20110029A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
ECSP10010518A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
NI200900159A (es) Moduladores de 2-aminopirimidina del receptor de histamina h4.
NI200800260A (es) Benzoimidazole - 2 - il pirimidinas y pirazinas como moduladores del receptor de histamina h4
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
GT201500243A (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
CR20130094A (es) Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
MX2020012012A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
PA8827501A1 (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3
CL2008003332A1 (es) Compuestos derivados de ciclopentano sustituido, como agentes hipotensores oculares; composicion oftalmologicamente aceptable; y uso para el tratamiento del glaucoma.
AR088764A1 (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
EA201590782A1 (ru) Оксирановые амины
BR112012010795A2 (pt) Formulações oftálmicas contendo gama lactams substituídas e métodos para uso das mesmas
NI201000131A (es) Tratamiento para trastornos relacionados con los ojos.
TR201902864T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
ECSP11011464A (es) Tia-triaza-ciclopentazulenos